129 related articles for article (PubMed ID: 23224125)
1. [Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme].
Wolf A; Reznicek L; Muhr J; Ulbig M; Kampik A; Haritoglou C
Ophthalmologe; 2013 Aug; 110(8):740-5. PubMed ID: 23224125
[TBL] [Abstract][Full Text] [Related]
2. Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD.
Scholler A; Richter-Mueksch S; Weingessel B; Vécsei-Marlovits PV
Wien Klin Wochenschr; 2014 Jun; 126(11-12):355-9. PubMed ID: 24696051
[TBL] [Abstract][Full Text] [Related]
3. Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care.
Reznicek L; Muhr J; Ulbig M; Kampik A; Mayer WJ; Haritoglou C; Neubauer A; Wolf A
Br J Ophthalmol; 2014 Oct; 98(10):1333-7. PubMed ID: 24903670
[TBL] [Abstract][Full Text] [Related]
4. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):639-44. PubMed ID: 20890777
[TBL] [Abstract][Full Text] [Related]
5. [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].
Maaß J; Sandner D; Matthé E
Ophthalmologe; 2017 Jun; 114(6):534-542. PubMed ID: 27743113
[TBL] [Abstract][Full Text] [Related]
6. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
[TBL] [Abstract][Full Text] [Related]
8. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG;
Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
10. [Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration].
Ziegler M; Heimes B; Book B; Dietzel M; Zeimer M; Spital G; Gutfleisch M; Pauleikhoff D; Lommatzsch A
Ophthalmologe; 2015 May; 112(5):435-43. PubMed ID: 25523611
[TBL] [Abstract][Full Text] [Related]
11. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.
Bloch SB; la Cour M; Sander B; Hansen LK; Fuchs J; Lund-Andersen H; Larsen M
Acta Ophthalmol; 2013 Feb; 91(1):42-7. PubMed ID: 22008284
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study.
Söderberg AC; Algvere PV; Hengstler JC; Söderberg P; Seregard S; Kvanta A
Br J Ophthalmol; 2012 May; 96(5):714-8. PubMed ID: 22241923
[TBL] [Abstract][Full Text] [Related]
13. [Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results].
Pfau M; Fassnacht-Riederle HM; Freiberg FJ; Wons JB; Wirth M; Becker MD; Michels S
Klin Monbl Augenheilkd; 2016 Aug; 233(8):945-50. PubMed ID: 27123887
[TBL] [Abstract][Full Text] [Related]
14. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
[TBL] [Abstract][Full Text] [Related]
15. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
[TBL] [Abstract][Full Text] [Related]
16. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
19. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity.
Muether PS; Hermann MM; Koch K; Fauser S
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):633-7. PubMed ID: 20865421
[TBL] [Abstract][Full Text] [Related]
20. One-year results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration.
Ozkaya A; Alkin Z; Agca A; Satici T; Karakucuk Y; Yazici AT; Demirok A
J Ocul Pharmacol Ther; 2013 Dec; 29(10):865-9. PubMed ID: 24053539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
